Clinical trial · Interventional
Prostatic Cancer Versus Androgen Deficiency
Localised Cancer of Prostate and Androgen Deficiency.
NCT02235142CI-TRIAL-00056058AndroCancompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Open study to make a comparison between hypogonadism and euogonadism patients regarding the severity of prostate cancer. The purpose of this study is to determine the importance of the relationship between the hormonal status and the type of the tumor at the time of surgical intervention as well as follow up of the patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Prostate | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Localised prostat cancer and androgen deficiency
- interventionNames
- Other: Blood sample
Primary outcomes (2)
- measure
- Testosteron Serum level
- timeFrame
- The day prior to surgery
- measure
- Gleason score
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male patients over than 18 years of age, with localized, stage I or II prostate cancer, not receiving local treatment (radiation, phototherapy, thermotherapy,…) or hormonal therapy, showing indication of radical prostatectomy. Exclusion Criteria: * Absence of radical prostatectomy indication * Patient received local or hormonal therapy prior to surgery * Patients already enrolled in other clinical study incompatible with the study * Patients on a treatment which can affect hormonal level (Prednisone, Ketoconazole, Abiraterone, Finasteride, Dutasteride)
References
Publications (2)
- DERIVEDPattou M, Neuzillet Y, Ghoneim T, Bosset PO, Vanalderverelt V, Bohin D, Lugagne PM, Soorojebally Y, Schneider M, Cathelineau X, Roupret M, Drouin SJ, Lebret T. Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching. Int J Urol. 2025 Sep;32(9):1243-1249. doi: 10.1111/iju.70142. Epub 2025 Jun 4. PMID 40462596
- DERIVEDNeuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M, Krish S, Roupret M, Drouin SJ, Comperat E, Galiano M, Cathelineau X, Validire P, Molinie V, Fiet J, Giton F, Lebret T, Botto H. Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Horm Cancer. 2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6. PMID 30293206